Genetic background of nontraumatic osteonecrosis of the femoral head in the Korean population

被引:64
作者
Chang, Jun-Dong [2 ]
Hur, Mina [1 ]
Lee, Sang-Soo [2 ]
Yoo, Je-Hyun [2 ]
Lee, Kyu Man [1 ]
机构
[1] Hallym Univ, Coll Med, Dept Lab Med, Hangang Sacred Heart Hosp, Seoul 150719, South Korea
[2] Hallym Univ, Coll Med, Dept Orthoped Surg, Seoul, South Korea
关键词
D O I
10.1007/s11999-008-0147-1
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Major thrombophilic mutations have been identified as risk factors for nontraumatic osteonecrosis of the femoral head (ONFH) in Caucasians. We asked whether the genetic background of patients with ONFH in the Korean population was similar. We analyzed factor V G1691A mutation (factor V Leiden), prothrombin G20210A mutation, and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in 71 patients (53 men, 18 women) with ONFH. We classified these patients as 51 alcohol-induced, 18 idiopathic, one steroid-induced, and one dysbaric. We recruited 200 normal control subjects (128 men, 72 women). We used multiplex PCR/restriction fragment length polymorphism for each genotyping. We observed neither factor V Leiden nor prothrombin G20210A mutation. Although methylenetetrahydrofolate reductase A1298C genotypes were not associated with osteonecrosis, methylenetetrahydrofolate reductase C677T variant genotypes increased the risk of ONFH compared with 677CC. Odds ratios of 677CT and 677CT+TT were 2.00 (95% confidence interval, 1.05-3.81) and 1.96 (95% confidence interval, 1.07-3.59), respectively, compared with 677CC. Our data suggest methylenetetrahydrofolate reductase C677T polymorphism plays a role in the pathogenesis of osteonecrosis in the Korean population. It also implies the genetic risk profile of ONFH may differ among ethnic populations. Level of Evidence: Level II, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.
引用
收藏
页码:1041 / 1046
页数:6
相关论文
共 29 条
[1]  
Angchaisuksiri P, 2000, AM J HEMATOL, V65, P119, DOI 10.1002/1096-8652(200010)65:2<119::AID-AJH5>3.3.CO
[2]  
2-#
[3]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[4]   Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee [J].
Björkman, A ;
Burtscher, IM ;
Svensson, PJ ;
Hillarp, A ;
Besjakov, J ;
Benoni, G .
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2005, 125 (01) :51-55
[5]   Factor V Leiden and prothrombin gene mutation [J].
Björkman, A ;
Svensson, PJ ;
Hillarp, A ;
Burtscher, IM ;
Rünow, A ;
Benoni, G .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2004, (425) :168-172
[6]   Epidemiology of factor V Leiden: Clinical implications [J].
De Stefano, V ;
Chiusolo, P ;
Paciaroni, K ;
Leone, G .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (04) :367-379
[7]   Hyperhomocysteinemia as a risk factor for deep-vein thrombosis [J].
denHeijer, M ;
Koster, T ;
Blom, HJ ;
Bos, GMJ ;
Briet, E ;
Reitsma, PH ;
Vandenbroucke, JP ;
Rosendaal, FR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :759-762
[8]  
Gardeniers JW, 1992, J JPN ORTHOP ASS, V66, P18
[9]  
Glueck CJ, 1997, CLIN ORTHOP RELAT R, P43
[10]  
GLUECK CJ, 2001, CLIN ORTHOP RELAT R, V386, P19